Optimizerx Corp (OPRX)

DataMeds AI, Inc. (Nasdaq: $MEDS ) launched its new corporate website, www.DataMedsAI.com, on September 21, 2026, with the redesigned site aligned to marketing initiatives now pending after two recently announced transactions. The launch follows the company's acquisition of Helomics Corporation's artificial intelligence cancer diagnostics lab from Axe Compute and the settlement of outstanding litigation tied to its 2023 acquisition of Wellgistics, LLC. DataMeds AI, Inc. is a B2i Digital Featured Company. See the company's in-depth profile at: https://b2idigital.com/datameds-ai-inc-1 Both the Helomics closing and the litigation settlement preceded the launch, and Gerald E. Commissiong ties them to the planned Health Lives Here consumer application: • DataMeds acquired Helomics Corporation's artificial intelligence cancer diagnostics lab, a CLIA-certified laboratory, from Axe Compute • The litigation settlement extinguished approximately $19 million in liabilities from the company's balance sheet and retired 364,099 common shares • Interim Co-CEO Gerald E. Commissiong said the Helomics closing and the litigation settlement leave the company ready to launch the Health Lives Here consumer application as it begins telling the DataMeds story to the broader market Regarding the new site, Gerald E. Commissiong, Interim Co-CEO of DataMeds, stated: "Our new corporate website represents the parent company's new branding. We have retooled our marketing efforts to be AI-centric so that we are able to get organic traction online as we begin to draw earned media interest in our story. We intend to soft launch the Health Lives Here app in short order." Read the full release: https://datamedsai.com/datameds-ai-unveils-new-corporate-website/ DataMeds AI, Inc. (Nasdaq: MEDS) (formerly Wellgistics Health, Inc.) is a Health IT company that focuses on the vertical integration of technology, pharmacy, pharmaceutical-adjacent and telemedicine business units to deliver a better healthcare experience for consumers. Headquartered in Tampa, Fla., DataMeds AI incorporates the artificial intelligence platform EinsteinRx™ and blockchain-enabled smart contracts platform PharmacyChain™ into the Health Lives Here mobile application, and its Corexa Health subsidiary provides pharmacy and pharmacy services, including the distribution of products developed by Tollo Health, LLC. Discover more Featured Companies, Featured Experts, and upcoming Featured Conferences at b2idigital.com. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. See the complete Disclosure at https://b2idigital.com/disclaimer. $OPRX, $HCAT, $PHR, $XLV

DataMEDS AI, Inc. (NASDAQ: $MEDS ) has settled litigation tied to the May 2023 Wellgistics, LLC purchase agreement, extinguishing liabilities of approximately $19 million that had been carried on its balance sheet. The Tampa-based Health IT company pairs its EinsteinRx artificial intelligence platform and PharmacyChain smart contracts platform with pharmacy, pharmaceutical-adjacent and telemedicine business units. DataMEDS AI, Inc. is a B2i Digital Featured Company. See the company's in-depth profile at: https://b2idigital.com/datameds-ai-inc-1 The consideration came in two parts, cash and retired shares, with the full terms in the company's SEC filing: • 364,099 shares of DataMEDS common stock were retired as part of the settlement agreement. • The company paid a total of $450,000 in cash for the settlement. • Additional terms are set out in a Form 8-K filed with the SEC and linked in the release. Regarding the company's focus following the settlement, Gerald E. Commissiong, Interim Co-CEO of DataMEDS, stated: "The Company is pleased to put this outstanding litigation behind it so it can focus on solving healthcare's biggest challenges for our clients through the vertical integration of healthcare delivery, and the compliant tokenization of pharmaceutical supply tracking and patient data." Read the full release: https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/datameds-ai-litigation-settlement-extinguishes-19-million-in-liabilit-1223546 DataMeds AI, Inc. (NASDAQ:MEDS) (formerly Wellgistics Health, Inc.) is a leading Health IT company that focuses on the vertical integration of technology, pharmacy, pharmaceutical-adjacent and telemedicine business units to deliver a better healthcare experience for consumers. Headquartered in Tampa, Fla., DataMeds AI incorporates the artificial intelligence platform EinsteinRx™ and blockchain-enabled smart contracts platform PharmacyChain™ into the Health Lives Here mobile application, and its Corexa Health subsidiary provides pharmacy and pharmacy services, including the distribution of products developed by Tollo Health, LLC. Discover more Featured Companies, Featured Experts, and upcoming Featured Conferences at b2idigital.com. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. See the complete Disclosure at https://b2idigital.com/disclaimer. $OPRX, $HCAT, $PHR, $XLV

$ATHR $CVAT $LXEO $OPRX $PBHC The underlying deal is real — it’s in CVAT’s SEC filing — but the “10.8¢ locked in, 270% return” framing leaves out some key details. The offer price isn’t fixed: it’s calculated as Net Price ÷ shares outstanding, and that gets recalculated at a record date 45 business days after the tender offer even opens, so the final per-share number can still move. The deal also isn’t done — EGS needs at least 90% of shares tendered, plus a separate $7M side-deal for Alchemy Beverages has to close too. And this plays out over months, not days, with the offer staying open 60+ business days and another 30+ after final pricing is set. The gap between the 3-6¢ trading price and the 10¢+ deal price isn’t free money sitting on the table — it’s the market pricing in real risk that this doesn’t close cleanly. Legit news, just not the guaranteed windfall it’s being sold as.

$CVAT Cavitation Technologies has execute a buyout for this company at 35 million $. This translate to 10.8c per share, you can finds this on the company SEC filing. The stock right now trades 3.9c, the buyout is for 10.8c. The buyer EGS, has already shown proof of funds, the Definitive Purchase Agreement has already been sign, and on Monday they will file the Tender Offer for submit your shares to the company. Buyout sp: 10.8c Current sp: 3.9c 270% Return on Investment, Tender will start Monday!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! https://www.compuserve.com/pf/story/0022/20260817/9811028.htm $PBHC $LXEO $ATHR $OPRX

$OPRX 🙃 ✨️

$OPRX $FNRG 👁

$OPRX oh dear my calls are going to shake 😳

$OPRX Q2 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.04 down -150.00% YoY • Reported revenue of $20.5M down -29.77% YoY • OptimizeRx Corp is reiterating its fiscal year 2026 guidance, expecting revenue of $95 million to $100 million and adjusted EBITDA of $21 million to $25 million for the full year.

https://www.marketbeat.com/earnings/reports/2026-8-12-optimizerx-co-stock/ $OPRX OptimizeRx Earnings Transcript

$OPRX https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&ref=320207725&type=HTML&symbol=OPRX&cdn=b322027f3de0537f02e3d19f5bbee83d&companyName=OptimizeRx+Corporation&formType=SCHEDULE+13G&formDescription=Statement+of+acquisition+of+beneficial+ownership+by+individuals&dateFiled=2026-07-22